ARS Pharmaceuticals, Inc. (SPRY)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$5.62-0.88%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SPRY
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -65.1% |
| Our one-year growth estimate | diamond | 47.6% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 112.7 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
SPRY — earnings miss
Dated 2026-08-13
of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or subject to the liabilities of that, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933 (the “Securities Act”), whether made before or after today’s date, regardless…
Why it matters: Earnings reports show how well a company is doing. They also show growth potential.
Worry ifThe earnings report shows a big loss. This is worse than what analysts expected.
Less concerning ifThe earnings report is better than expected. This shows better financial stability.
Why it matters: Lower SG&A expenses are crucial for reaching cash flow breakeven by 2027.
Supportive ifQ3 SG&A expenses are under $50 million. This shows good cost management.
Worry ifQ3 SG&A expenses are over $60 million. This shows problems with financial discipline.
Why it matters: More state adoptions would enhance neffy's market reach and sales potential.
Supportive ifAt least three more states add neffy to their Medicaid formularies without limits.
Worry ifNo new states add neffy to their Medicaid formularies by early 2027.
Why it matters: Strong revenue growth helps keep ARS Pharma stable and strong in the market.
Supportive ifQ2 2026 total revenue exceeds $22.7 million.
Worry ifQ2 2026 total revenue falls below $20 million.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$278 on $10,000 · ±2.8% | How much price usually moves either way. |
| Bad day | $679 loss on $10,000 · 6.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,072 loss on $10,000 · 60.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Growing revenue shows success in the commercial strategy and gaining market share.
Supportive ifQ3 neffy net product revenue is over $30 million. This shows strong market adoption.
Worry ifQ3 neffy net product revenue is under $25 million. This suggests weak sales.
Why it matters: More market share among key prescribers shows the new strategy is working.
Supportive ifField-targeted accounts show a market share increase above 8% in the next quarter.
Worry ifMarket share in field-targeted accounts fails to increase or declines.
Why it matters: The interim data will show if the intranasal epinephrine can help treat CSU. This could open a new market for ARS Pharma.
Supportive ifInterim data from the Phase 2b trial shows good results for intranasal epinephrine in CSU.
Worry ifNew data from the Phase 2b trial shows no real benefit for intranasal epinephrine in CSU.
Why it matters: Negative cash flow has been a concern. Improvement would indicate better financial health.
Supportive ifOperating cash flow turns positive in Q2. This shows stronger financial stability.
Worry ifOperating cash flow remains negative or worsens in Q2.
Why it matters: ARS Pharma needs more revenue to break even by 2027. This shows their strategy is working.
Supportive ifU.S. net product revenue for Q3 exceeds $26.2 million.
Worry ifU.S. net product revenue for Q3 falls below $26.2 million.
Why it matters: Sector growth affects ARS's performance. A slowdown could impact revenue expectations.
Worry ifHealthcare sector revenue growth falls below its median. This suggests possible challenges ahead.
Less concerning ifHealthcare sector revenue growth remains strong or improves.
Why it matters: Better cash flow is important for stability. It helps keep operations running.
Supportive ifOperating cash flow is expected to be positive soon.
Worry ifOperating cash flow may stay negative or get worse.
Why it matters: A big reduction would show good cost management. This supports reaching cash flow breakeven.
Supportive ifSG&A expenses for 2H 2026 are below $50 million. This confirms cost-cutting efforts.
Worry ifSG&A expenses stay above $70 million. This shows ongoing financial problems.
Why it matters: Interim data will show if the intranasal epinephrine can effectively treat CSU flares. This could open a new market for ARS Pharma.
Supportive ifInterim data from the Phase 2b trial shows positive results for the treatment of CSU.
Worry ifNew data shows no clear benefit in treating CSU flares.